enGene Reports Third Quarter 2024 Financial Results and Provides a Business UpdateBusiness Wire • 09/10/24
enGene Reports Second Quarter 2024 Financial Results and Provides a Business UpdateBusiness Wire • 06/14/24
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of DirectorsBusiness Wire • 05/15/24
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual MeetingPRNewsWire • 05/02/24
enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical DevelopmentPRNewsWire • 04/09/24
enGene Reports First Quarter 2024 Financial Results and Recent Corporate ProgressPRNewsWire • 03/11/24
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines CompanyAccesswire • 11/02/23